Evidence map›Paper›PMID 23392399›Full record

Trial reportJAMA ophthalmology2013

Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial.

Rajeev H Muni, Radha P Kohly, Eudocia Q Lee, JoAnn E Manson, Richard D Semba, Debra A Schaumberg

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. The Diabetes Visual Function Supplement Study (DiVFuSS).The British journal of ophthalmology · 2016
    Trial
  3. Review
  4. Higher diabetes genetic load in proliferative diabetic retinopathy in South India: The South Indian GeNetics of DiAbeTic Retinopathy (SIGNATR) study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 2 countries.

Rajeev H MuniDepartment of Ophthalmology and Vision Sciences, University of Toronto, St Michael’s Hospital, Toronto, Canada. rajeev.muni@utoronto.ca
Radha P Kohly
Eudocia Q Lee
JoAnn E Manson
Richard D Semba
Debra A Schaumberg
Brigham and Women's Hospital · USHarvard University Press · USJohns Hopkins University · USSt. Michael's Hospital · CAUniversity of Toronto · CAUniversity of Utah · US

Funding

Oxidative stress and the pathogenesis of sarcopenia and disability in older womenR01AG027012 · NIA · JOHNS HOPKINS UNIVERSITY · PI SEMBA, RICHARD D · 2005 to 2018
$3.6M
Molecular Risk Factors for Age-Related MaculopathyR01EY013834 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHAUMBERG, DEBRA A · 2002 to 2004
$945k
NEI NIH HHS R01 EY013834NIA NIH HHS R01 AG027012
6 · The paper itself

Abstract

importanceThis study demonstrates that increasing quintiles of baseline high-sensitivity C-reactive protein (hsCRP) level may be associated with higher risk of incident clinically significant macular edema, the leading cause of vision loss in working-aged individuals in North America.

objectiveTo determine whether baseline levels of hsCRP and intercellular adhesion molecule 1 (ICAM-1) predict development and progression of diabetic retinopathy (DR), clinically significant macular edema (CSME), retinal hard exudates, and proliferative DR in the Diabetes Control and Complications Trial (DCCT) cohort.

designThe DCCT was a large multicenter randomized controlled clinical trial.

settingTwenty-nine medical centers in the United States and Canada.

participantsThe DCCT population consisted of 1441 subjects with type 1 diabetes mellitus aged 13 to 39 years at study entry.

interventionWe measured levels of hsCRP, ICAM-1, vascular cell adhesion molecule 1, and tumor necrosis factor α receptor 1 in stored baseline blood samples.

main outcome measuresWe assessed the association of levels of hsCRP, ICAM-1, vascular cell adhesion molecule 1, and tumor necrosis factor α receptor 1 with incident DR end points ascertained from grading of standardized 7-field stereoscopic retinal color photographs taken at baseline and every 6 months during follow-up.

resultsAfter adjustment for randomized treatment assignment and other factors, we observed a statistically significant association between hsCRP and risk of CSME, with a relative risk (RR) for the top vs bottom quintile of 1.83 (95% CI, 0.94-3.55; P for trend = .01). Similarly, for the development of retinal hard exudates, the RR for the top vs bottom quintile of hsCRP level was 1.78 (95% CI, 0.98-3.25; P for trend = .004), whereas for ICAM-1 level, the RR comparing the top vs bottom quintiles was 1.50 (95% CI, 0.84-2.68; P for trend = .05). There were no statistically significant associations between baseline VCAM-1 or tumor necrosis factor α receptor 1 levels and risk of any of the DR end points. CONCLUSIONS AND RELEVANCE: After adjusting for known risk factors, increasing quintiles of baseline hsCRP level may be associated with higher risk of incident CSME and macular hard exudate in the DCCT cohort. Circulating levels of ICAM-1 may also be associated with the development of retinal hard exudates.

Indexed as

AdolescentAdultBiomarkersChromatography, High Pressure LiquidC-Reactive ProteinDiabetes Mellitus, Type 1Diabetic RetinopathyEnzyme-Linked Immunosorbent AssayGlycated HemoglobinHumansIntercellular Adhesion Molecule-1Macular EdemaNephelometry and TurbidimetryProspective StudiesReceptors, Tumor Necrosis Factor, Type IRisk AssessmentBiomarkersC-Reactive ProteinGlycated Hemoglobinhemoglobin A1c protein, humanIntercellular Adhesion Molecule-1Receptors, Tumor Necrosis Factor, Type IVascular Cell Adhesion Molecule-1

Identifiers

PMID23392399
PMCPMC3625475
OpenAlexW2025833281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.